Articles
By Wayne Kuznar
Men with prostate cancer are often treated with hormone therapy (androgen deprivation therapy [ADT]), but this treatment can have unpleasant and even harmful side effects, including metabolic abnormalities that lead to diabetes mellitus (DM) and cardiovascular disease (CVD).
By Wayne Kuznar
Monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy for chronic myelogenous leukemia (CML) may help guide the decision to switch therapy and the timing of progression to second- and third-line therapy, said Jerald P. Radich, MD, at the 2014 annual meeting of the National Comprehensive Cancer Network (NCCN).
About 50% of cancer patients —90% in some subsets—develop cancer- or chemotherapy-related anemia.
In this month’s issue of The Oncology Pharmacist (TOP), we present our coverage of the news from the Hematology/Oncology Pharmacy Association (HOPA) 10th Annual Conference.
Within the oncology drug development pipeline, “multiple myeloma is one of the more intriguing spaces,” according to R. Donald Harvey, PharmD, BCOP, who said one reason for his excitement is the emergence of monoclonal antibodies.
By Wayne Kuznar
Reactive management and attention to possible infection is usually sufficient to treat dermatologic toxicities associated with targeted cancer therapies, said Barbara Burtness, MD, professor of medical oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania.
“The 340B pricing program will continue to be modified to improve oversight and compliance, but it is here to stay,” according to Ron Schleif, MBA, BSPharm, cofounder and president of Oncology Reimbursement Management, a consulting firm.
The Oncology Nursing Society (ONS) 39th Annual Congress attracted almost 3000 attendees from the United States and other parts of the world. Interviews with a random sample of attendees revealed that a common theme about what drew them to the meeting was the desire to expand their horizons—to gain new knowledge, meet new people, or to breathe new life into their careers.
Attendees at the 10th Annual Conference of the Hematology/Oncology Pharmacy Association (HOPA) said there’s no place like HOPA for reconnecting with friends and colleagues in the pharmacy world, and learning from face-to-face time with their peers.
Both oral and intravenous chemotherapy agents, and other drugs used to treat patients with cancer, can be hazardous to medical personnel who prepare, dispense, and administer these drugs, as well as to patients and their families. The Oncology Pharmacist spoke about safe-handling procedures and guidelines with Anne Marie Oberle, PharmD, BCOP, Advance Practice Clinical Oncology Pharmacist at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.